Detecting Treatment Emergent Adverse Events in Clinical Trials: A Comparison of Spontaneously Reported and Solicited Collection Methods

Author： Wernicke Joachim F.   Faries Douglas   Milton Denái   Weyrauch Karen  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.28, Iss.11, 2005-01, pp. : 1057-1063

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Statistical Methods to Analyze Adverse Events Data of Randomized Clinical Trials

By Siddiqui Ohidul  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 5, 2009-09 ,pp. : 889-899

Taylor & Francis Ltd

Access to resources Recommend Favorite

Treatment-emergent adverse events associated with atypical antipsychotics

By Cha Danielle S   McIntyre Roger S  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 11, 2012-08 ,pp. : 1587-1598

Informa Healthcare

Access to resources Recommend Favorite

Efalizumab: a review of events reported during clinical trials and side effects

By Scheinfeld Noah  

Expert Opinion on Drug Safety, Vol. 5, Iss. 2, 2006-03 ,pp. : 197-209

Informa Healthcare

Access to resources Recommend Favorite

Serious adverse events reported with trastuzumab

By  

Inpharma, Vol. 1, Iss. 1238, 2000-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Niacin Extended-Release Therapy in Phase III Clinical Trials is Associated with Relatively Low Rates of Drug Discontinuation due to Flushing and Treatment-Related Adverse Events: A Pooled Analysis

By Brinton Eliot A.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 3, 2011-06 ,pp. : 179-187

Adis International

Access to resources Recommend Favorite